TrialJournal for immunotherapy of cancer2024

High peripheral T cell diversity is associated with lower risk of toxicity and superior response to dual immune checkpoint inhibitor therapy in patients with metastatic NSCLC.

Mehmet Altan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.